- Home
- CRT vs CLSD Comparison
CRT vs CLSD Comparison
Compare CRT & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRT
- CLSD
- Stock Information
- Founded
- CRT 1991
- CLSD 2011
- Country
- CRT United States
- CLSD United States
- Employees
- CRT N/A
- CLSD N/A
- Industry
- CRT Oil & Gas Production
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- CRT Energy
- CLSD Health Care
- Exchange
- CRT Nasdaq
- CLSD Nasdaq
- Market Cap
- CRT 65.1M
- CLSD 68.4M
- IPO Year
- CRT 1992
- CLSD 2016
- Fundamental
- Price
- CRT $9.58
- CLSD $0.45
- Analyst Decision
- CRT
- CLSD Hold
- Analyst Count
- CRT 0
- CLSD 4
- Target Price
- CRT N/A
- CLSD $4.33
- AVG Volume (30 Days)
- CRT 19.2K
- CLSD 12.7M
- Earning Date
- CRT 01-01-0001
- CLSD 08-11-2025
- Dividend Yield
- CRT 9.32%
- CLSD N/A
- EPS Growth
- CRT N/A
- CLSD N/A
- EPS
- CRT 0.99
- CLSD N/A
- Revenue
- CRT $6,834,116.00
- CLSD $3,764,000.00
- Revenue This Year
- CRT N/A
- CLSD $143.33
- Revenue Next Year
- CRT N/A
- CLSD N/A
- P/E Ratio
- CRT $9.58
- CLSD N/A
- Revenue Growth
- CRT N/A
- CLSD N/A
- 52 Week Low
- CRT $8.88
- CLSD $0.29
- 52 Week High
- CRT $13.31
- CLSD $1.65
- Technical
- Relative Strength Index (RSI)
- CRT 42.09
- CLSD 34.58
- Support Level
- CRT $9.49
- CLSD $0.29
- Resistance Level
- CRT $9.86
- CLSD $0.62
- Average True Range (ATR)
- CRT 0.13
- CLSD 0.11
- MACD
- CRT -0.01
- CLSD -0.03
- Stochastic Oscillator
- CRT 37.78
- CLSD 25.18
About CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.